Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
74.30
+0.13 (0.18%)
Oct 31, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 21 analysts that cover Ionis Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $79.67, which forecasts a 7.23% increase in the stock price over the next year. The lowest target is $39 and the highest is $100.
Price Target: $79.67 (+7.23%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 5 | 6 | 8 | 9 |
| Buy | 4 | 4 | 5 | 5 | 6 | 8 |
| Hold | 6 | 5 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 18 | 17 | 14 | 15 | 18 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $59 → $99 | Strong Buy | Maintains | $59 → $99 | +33.24% | Oct 30, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $90 → $94 | Buy | Maintains | $90 → $94 | +26.51% | Oct 30, 2025 |
| Barclays | Barclays | Buy Maintains $80 → $95 | Buy | Maintains | $80 → $95 | +27.86% | Oct 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $95 → $100 | Strong Buy | Maintains | $95 → $100 | +34.59% | Oct 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $80 → $82 | Buy | Maintains | $80 → $82 | +10.36% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
874.50M
from 705.14M
Increased by 24.02%
Revenue Next Year
909.97M
from 874.50M
Increased by 4.06%
EPS This Year
-2.62
from -3.04
EPS Next Year
-3.28
from -2.62
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,000.0M | 1.2B | |||
| Avg | 874.5M | 910.0M | |||
| Low | 816.1M | 668.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.8% | 38.1% | |||
| Avg | 24.0% | 4.1% | |||
| Low | 15.7% | -23.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.66 | -1.32 | |||
| Avg | -2.62 | -3.28 | |||
| Low | -2.88 | -4.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.